Ondine Biomedical (AIM: OBI)

Last close As at 23/11/2024

9.00

−5.25 (−36.84%)

Market capitalisation

GBP29m

Latest Insights

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (41.0) (41.9) (77.2)
Relative (39.0) (41.8) (77.5)
52 week high/low 41.0p/9.0p

Financials

Ondine Biomedical has announced the initiation of its first NHS pilot study for Steriwave, the company’s lead product for nasal photodisinfection. The pilot is based at the Mid Yorkshire Teaching NHS Trust and will assess the effectiveness of Ondine’s technology in preventing surgical site infections (SSIs). The study will have a duration of six months and involve 500 hip and knee surgery patients using Steriwave for nasal decolonisation prior to surgery. With hospital-associated infections (HAIs) having an annual cost of around £2.1bn for the NHS, we believe there may be a significant opportunity for Steriwave in the UK and, therefore, the outcome of this pilot could represent an important catalyst Ondine.

Thematics

thematic

Healthcare

Healthcare-focused trusts: A sector on the mend

thematic

TMT

MediaWatch – One step forward, two steps back

thematic

Consumer

ConsumerWatch – Don’t look down

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free